1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU’s DARWIN Project To Expand Geographical Reach With 10 New Data Partners

 
• By Eliza Slawther

The EU DARWIN initiative is expected to deliver more than 70 real-world data studies this year and twice this figure from 2025 onwards to enhance European decisions on medicines.

European Health Data Space
• Source: Shutterstock

The European Medicines Agency is selecting 10 new data partners to join the DARWIN EU initiative in the coming months to increase the “geographical coverage” of the project, an agency spokesperson told the Pink Sheet.

The agency is currently screening expressions of interest from an open call it put out for new data partners and will select the next 10 data partners to be onboarded in 2024, the spokesperson added

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.